Cincinnati Public Radio: Researchers Zeroing In On Blood Vessels to Prevent COVID 'Long-Haulers'
UC physicians discuss clinical trial designed to help COVID patients
Richard Becker, MD, and Duncan Hite, MD, both professors in the UC College of Medicine and UC Health physicians, spoke with WVXU reporter Ann Thompson about a phase 2 clinical trial underway at UC/UC Health to determine the safety and efficacy of the drug razuprotafib in treating COVID-19 patients. UC is one of 20 sites across the nation participating in the trial.
Researchers say this drug could possibly prevent "long-haulers syndrome." Razuprotafib is already used to treat diabetes and renal disease. By zeroing in on blood vessels to make them healthier, it's hoped COVID patients can benefit, too. Becker, director of the UC Heart, Lung and Vascular Institute, and Hite, director of medical critical care at UC Health, are part of a clinical trial conducted by Aerpio Pharmaceuticals.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.